Overview
OPTH market data
Price History
OPTH price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.16 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.96 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -844.6% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.15 – $11.40 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $37.5M · P/B 5.67 · P/S 126.75.
Company News
Optimi Health Completes Psilocybin Export to Australia for Patients With Treatment-Resistant DepressionGlobenewswire Inc · Jun 29, 2026, 1:15 PM
Optimi Health Exports Third Shipment Of Its 5Mg Psilocybin Product To Australia Since September 2025Benzinga · Jun 29, 2026, 1:10 PM
SRx Health Solutions Closes EMJX Acquisition and Launches AI-Driven Platform Strategy Under New Name and Brand, SRX Global, Focused on Investments in High-Conviction Operating Companies and AssetsBenzinga · Jun 18, 2026, 1:15 PM
Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical ResearchBenzinga · Jun 16, 2026, 5:15 PM
Optimi Health Completes Production Of Two Microdose Psilocybin Finished Drug Products, Formulated At 1 Mg And 2 Mg Dosages; Products Available To Authorized Clinical Research OrganizationsBenzinga · Jun 16, 2026, 12:40 PM
Optimi Health Completes Commercial Psilocybin Production to Address Treatment-Resistant Depression in AustraliaBenzinga · Jun 2, 2026, 5:15 PM
SRx Health Solutions Invests In Optimi Health To Tap Into Psychedelic Industry; Amounts Not DisclosedBenzinga · May 21, 2026, 1:10 PM
Optimi Health Prices Underwritten Public Offering Of 2.40M Common Shares At $6.25/ShrBenzinga · May 20, 2026, 3:40 PM
Trading Halt: Halt status updated at 9:50:00 AM ET: Quotation Resumption: IPO Security - Released for QuotationBenzinga · May 20, 2026, 1:55 PM